Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773507 | 0.82 | ESR1 (0.46) | ESR1ESR2HSD17B1 | |
| SCHEMBL773508 | 0.82 | ESR1 (0.46) | ESR1ESR2HSD17B1 | |
| SCHEMBL796161 | 0.77 | CYP19A1 (0.58) | ESR1ESR2CYP19A1HSD17B1 | |
| SCHEMBL796268 | 0.72 | ESR1 (0.52) | ESR1ESR2CYP19A1HSD17B1BRAF | |
| SCHEMBL796201 | 0.68 | ESR1 (0.60) | ESR1ESR2CYP19A1 | |
| SCHEMBL771976 | 0.68 | ESR1 (1.00) | ESR1ESR2CYP19A1BRAF | |
| SCHEMBL773924 | 0.68 | ESR1 (1.00) | ESR1ESR2CYP19A1BRAF | |
| SCHEMBL12544455 | 0.68 | ESR1 (1.00) | ESR1ESR2CYP19A1BRAF | |
| SCHEMBL18204087 | 0.66 | ESR1 (0.68) | ESR1ESR2CYP19A1BRAF | |
| SCHEMBL795974 | 0.66 | ESR1 (0.41) | ESR1ESR2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071455-A1 | 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS SELECTIVE ER-BETA AGONISTS | ENDECE, LLC | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071455-A1 | 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS SELECTIVE ER-BETA AGONISTS | ESR2, ESR1, ESRRG | ESR1 2/4885ESR2 1/4885CYP19A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.